News
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI changes the date for publication of Interim Report 3 2021/22
The reason for the change of date is to allow management and staff to participate in the newly decided rights issue by purchasing shares.
Continued Sales Growth for PHI
PHI’s sales in November – January gained 240 % and amounted to 2.7 (0.8) MSEK. Sales over the past four fiscal quarters (Feb 2021 – Jan 2022) amount to 8.8 (2.3) MSEK.
PHI Moves to New Premises
As of today, Phase Holographic Imaging’s registered office is Skiffervägen 48, 224 78 Lund, Sweden.
The Board of Directors proposes decision on a rights issue of units and a directed issue of convertibles
The Board of Directors of Phase Holographic Imaging has today decided to propose that the Extraordinary General Meeting shall decide on a rights issue, which initially can provide the company with approx. SEK 72.4 million.
PHI Introduces Non-invasive Fluorescence
Currently, the HoloMonitor fluorescence unit is being prepared for its first users.
Interim Report 2 2021/22
Strong sales growth for the 3rd consecutive quarter. Recent advancements in regenerative medicine create additional growth potential in clinical applications for the company.
Interim Report 1 2021/22
The strategic shift of sales and marketing continues to prove itself. Despite being a “slow summer quarter”, sales during May – July surpassed sales during any previous quarter.
PHI Enters Regenerative Medicine Partnership
PHI and RegenMed Development Organization have entered a partnership to advance large-scale biomanufacturing of cell-based therapies.
Year-end Report 2020/21
The strategic shift to focus on digital sales & marketing has been successful, reflected in the sales increase during the latter part of the fiscal year.
Growing Number of Bio-engineering Companies Purchase HoloMonitor
The regenerative medicine company Pandorum Technology recently purchased a complete HoloMonitor system.